David Gilot
Overview
Explore the profile of David Gilot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Prouteau A, Mottier S, Primot A, Cadieu E, Bachelot L, Botherel N, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053440
Mucosal melanoma (MM) is a rare, aggressive clinical cancer. Despite recent advances in genetics and treatment, the prognosis of MM remains poor. Canine MM offers a relevant spontaneous and immunocompetent...
12.
Bevant K, Desoteux M, Angenard G, Pineau R, Caruso S, Louis C, et al.
Hepatol Commun
. 2021 Nov;
6(5):1157-1171.
PMID: 34825776
Transforming growth factor beta (TGF-β) plays a key role in tumor progression, notably as a potent inducer of epithelial-mesenchymal transition (EMT). However, all of the molecular effectors driving TGFβ-induced EMT...
13.
Lagarrigue S, Lorthiois M, Degalez F, Gilot D, Derrien T
Mamm Genome
. 2021 Nov;
33(2):248-270.
PMID: 34773482
Animal genomes are pervasively transcribed into multiple RNA molecules, of which many will not be translated into proteins. One major component of this transcribed non-coding genome is the long non-coding...
14.
Krishnamurthy S, Gilot D, Ahn S, Lam V, Shin J, Guillemin G, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680327
As the second and third leading cancer-related death in men and the world, respectively, primary liver cancer remains a major concern to human health. Despite advances in diagnostic technology, patients...
15.
Jakobczyk H, Jiang Y, Debaize L, Soubise B, Avner S, Serandour A, et al.
Leukemia
. 2021 Sep;
36(2):549-554.
PMID: 34535762
No abstract available.
16.
Amendola M, Bedel A, Buj-Bello A, Carrara M, Concordet J, Frati G, et al.
Hum Gene Ther
. 2021 Sep;
32(19-20):1059-1075.
PMID: 34494480
Recent advances in genome editing tools, especially novel developments in the clustered regularly interspaced short palindromic repeats associated to Cas9 nucleases (CRISPR/Cas9)-derived editing machinery, have revolutionized not only basic science...
17.
Gautron A, Bachelot L, Aubry M, Leclerc D, Quemener A, Corre S, et al.
EMBO Mol Med
. 2021 Mar;
13(5):e13466.
PMID: 33724679
Most genetic alterations that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non-genetic mechanisms...
18.
Leclerc D, Staats Pires A, Guillemin G, Gilot D
Curr Opin Immunol
. 2021 Jan;
70:15-26.
PMID: 33429228
Sustained transcriptional activation of the aryl hydrocarbon receptor (AhR) promotes tumour growth and impairs the immune defence, at least for cutaneous melanoma and glioma. AhR ligands are produced by the...
19.
Gautron A, Migault M, Bachelot L, Corre S, Galibert M, Gilot D
Pigment Cell Melanoma Res
. 2020 Dec;
34(5):836-852.
PMID: 33305505
In the animal kingdom, skin pigmentation is highly variable between species, and it contributes to phenotypes. In humans, skin pigmentation plays a part in sun protection. Skin pigmentation depends on...
20.
Quemener A, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert M
Wiley Interdiscip Rev RNA
. 2020 Apr;
11(5):e1594.
PMID: 32233021
Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs...